Rob van Wijk
Assistant professor
- Name
- Dr. R.C. van Wijk
- Telephone
- +31 71 527 4505
- r.c.van.wijk@lacdr.leidenuniv.nl
- ORCID iD
- 0000-0001-7247-1360
Rob van Wijk is Principal Investigator “Translational Immuno-Pharmacology” at the Division of Systems Pharmacology & Pharmacy.
More information about Rob van Wijk
News
-
‘A few nerves before lectures show that my work matters’ -
With 30 million dollars, this consortium aims to tackle tuberculosis -
Leiden researchers join forces against tuberculosis -
Pharmacologist Rob van Wijk is highlighted author of the month -
‘Test medicines after five days’ -
Rob van Wijk has won the oral presentations of the National PhD Competition during the FIGON Dutch Medicine Days -
Rob van Wijk discusses the role of zebrafish in drug discovery -
Leiden PhD team in finals international pharmacological competition
Rob van Wijk performed his PhD research on ‘Translational pharmacokinetics-pharmacodynamics in zebrafish’ at the Leiden Academic Centre for Drug Research in collaboration with the Institute of Biology Leiden, under the supervision of prof. dr. Piet Hein van der Graaf, prof. dr. Herman Spaink, and dr. Elke Krekels. This multi-disciplinary project with collaborators from three different research institutes of Leiden University and two international partners, Uppsala University and Dana Farber Cancer Institute, Harvard University, focussed on the quantification of internal drug exposure over time, and drug effect over it concentration for three different drugs (paracetamol, isoniazid, isotretinoin) in the zebrafish and zebrafish larva.
Rob van Wijk continued his academic career with two postdoctoral positions. From March 2020 to March 2022, he worked at Uppsala University with prof. dr. Ulrika Simonsson. In this postdoc, he consolidated his advanced computational skills in pharmacometrics, working on preclinical and clinical projects. He collaborated in 2 consortia, and developed innovative analysis methods that became standard in international preclinical and clinical tuberculosis projects. He also analysed a Phase 3 COVID-19 vaccination trial, for which he developed novel techniques to include seasonality of pandemic waves, and a reproducible, automated analysis method to accelerate the trial analysis.
For his second postdoc (May 2022-Oct 2023), Rob van Wijk joined prof. dr. Rada Savic’s group at the University of California, San Francisco (UCSF), which has a strong track record in Global Health drug development, such as shortening tuberculosis treatment. To train himself in achieving an impact on drug development, he collaborated with stakeholders such as big pharma, non-profit organisations (TB Alliance, Gates Foundation), and governmental institutes (NIH/CDC, FDA) to prepare for, and analyse clinical trials (Phase 1-3) in tuberculosis and HIV. This included the development of an open-access translational tool to predict Phase 2a clinical results based on preclinical data, through which he supported the development of four novel drug candidates.
Currently, Rob van Wijk is a principal investigator “Translational Immuno-Pharmacology” and assistant professor at the Division of Systems Pharmacology and Pharmacy at Leiden University.
Assistant professor
- Science
- Leiden Academic Centre for Drug Research
- LACDR/Pharmacology
- Aslam E., Gijasi A., Perner C., Wijk R. van, Märtson A., Westen G.J.P. van, Bot I., Heitman L.H. & Mashaghi A. (2024), Chapter 26 - Immunobiology and pharmacology of neuropeptide substance P. In: Vink R. (Ed.), Substance P : From Pain to Cancer: Academic Press. 625-660.
- Wijk R.C. van, Mockeliunas L., Upton C.M., Peter J., Diacon A.H. & Simonsson U.S.H. (2023), Seasonal influence on respiratory tract infection severity including COVID‐19 quantified through Markov Chain modeling, CPT: Pharmacometrics & Systems Pharmacology 12(9): 1250-1261.
- Wijk R.C., Imperial M.Z. Savic R.M. & Solans B.P. (2023), Pharmacokinetic analysis across studies to drive knowledge‐integration: a tutorial on individual patient data meta‐analysis (IPDMA), CPT: Pharmacometrics & Systems Pharmacology 12(9): 1187-1200.
- Wijk R.C. van, Ainhoa L., Sudhakar P.K., Sonnenkalb L., Gaudin C., Hoffmann E., Dremierre B., Aguilar-Ayala D.A., Molin M.D., Rybniker J., De Giorgi S., Cioetto-Mazzabò L., Segafreddo G., Manganelli R., Degiacomi G., Recchia D., Pasca M.R.,Simonsson U.S.H. & Ramón-García S. (2023), Implementing best practices on data generation and reporting of mycobacterium tuberculosis in vitro assays within the ERA4TB consortium, iScience 26(4): 106411.
- Mockeliunas L., Faraj A., Wijk R.C. van, Upton C.M., Hoogen G. van den, Diacon A.H. & Simonsson U.S.H. (2023), Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development, Frontiers in Pharmacology 14: 1150243.
- Faraj A., Wijk R.C. van, Neuman L., Desai S., Blouse G.E., Knudsen T. & Simonsson U.S.H. (2023), Model‐informed pediatric dose selection of marzeptacog alfa (activated): an exposure matching strategy, CPT: Pharmacometrics & Systems Pharmacology 12(7): 977-987.
- Ernest J.P., Goh J.J.N., Strydom N., Wang Q., Wijk R.C. van, Zhang N., Deitchman A., Nuermberger E. & Savic R.M. (2023), Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs, European Respiratory Journal 62(2): 2300165.
- Wijk R.C. van & Simonsson U.S.H. (2022), Finding the right hazard function for time‐to‐event modeling: a tutorial and shiny application, CPT: Pharmacometrics & Systems Pharmacology 11(8): 991-1001.
- Upton C.M., Wijk R.C. van, Mockeliunas L., Simonsson U.S.H., McHarry K., Hoogen G. van den, Muller C.,Delft Arne von, Westhuizen H.-M. van der, Crevel R. van, Walzl G., Baptista P.M., Peter J. & Diacon A.H. (2022), Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: a double-blind, randomised, controlled, phase 3 trial, EClinicalMedicine 48: 101414.
- De Jager V., Gupte N., Nunes S., Barnes G.L., Wijk R.C. van, Mostert J., Dorman S.E., Abulfathi A. A., Upton C.M., Faraj A., Nuermberger E.L., Lamichhane G., Svensson E.M., Simonsson U.S.H., Diacon A.H. & Dooley K.E. (2022), Early bactericidal activity of meropenem plus clavulanate (with or without rifampin) for tuberculosis: the COMRADE randomized, phase 2A clinical trial, American Journal of Respiratory and Critical Care Medicine 205(10): 1228-1235.
- Tang X., Spaink H.A.J., Wijk R.C. van & Verbeek F.J. (2020), Segmentation-driven optimization for iterative reconstruction in optical projection tomography: an exploration, IEEE Transactions on Computational Imaging 6: 1537-1547.
- Wijk R.C. van (6 February 2020), Translational pharmacokinetics-pharmacodynamics in zebrafish: integration of experimental and computational methods (Dissertatie. Leiden Academic Centre for Drug Research (LACDR), Faculty of Science, Leiden University). Supervisor(s) and Co-supervisor(s): Graaf P.H. van der & Spaink H.P., Krekels E.H.J.
- Wijk R.C. van, Sar A.M. van der, Krekels E.H.J., Verboom T., Spaink H.P., Simonsson U.S.H. & Graaf P.H. van der (2020), Quantification of natural growth of two strains of Mycobacterium marinum for translational anti‐tuberculosis drug development, Clinical and Translational Science 13(6): 1060-1064.
- Wijk R.C. van, Hu W.B., Dijkema S.M., Berg D. van den, Liu J., Bahi R., Verbeek F.J., Simonsson U.S.H., Spaink H.P., Graaf P.H. van der & Krekels E.H.J. (2020), Anti-tuberculosis effect of isoniazid scales accurately from zebrafish to humans, British Journal of Pharmacology 177(24): 5518-5533.
- Wijk R.C. van, Krekels E.H.J., Kantae V., Harms A.C., Hankemeier T., Graaf P.H. van der & Spaink H.P. (2019), Impact of post-hatching maturation on the pharmacokinetics of paracetamol in zebrafish larvae, Scientific Reports 9: 2149.
- Wijk R.C. van, Krekels E.H.J., Kantae V., Ordas A., Kreling T., Harms A.C., Hankemeier T., Spaink H.P. & Graaf P.H. van der (2019), Mechanistic and quantitative understanding of pharmacokinetics in zebrafish larvae through nanoscale blood sampling and metabolite modelling of paracetamol, Journal of Pharmacology and Experimental Therapeutics 371(1): 15-24.
- Wong Y.C., Ilkova T.I., Wijk R.C. van, Hartman R.J. & Lange E.C.M. de (2018), Development of a population pharmacokinetic model to predict brain distribution and dopamine D2 receptor occupancy of raclopride in nonanesthetized rat, European Journal of Pharmaceutical Sciences 111: 514–525.
- Schulthess P., Wijk R.C. van, Krekels E.H.J., Yates J.W.T., Spaink H.P. & Graaf P.H. van der (2018), Outside-in systems pharmacology combines innovative computational methods with high-throughput whole vertebrate studies, CPT: Pharmacometrics and Systems Pharmacology 7(5): 285-287.
- Wijk R.C. van, Krekels E.H.J., Hankemeier T., Spaink H.P. & Graaf P.H. van der (2017), Systems pharmacology of hepatic metabolism in zebrafish larvae, Drug Discovery Today: Disease Models 22: 27-34.
- Guo Y., Wijk R.C. van, Krekels E.H.J., Spaink H.P., Graaf P.H. van der & Verbeek F.J. (2017), Multi-modal 3D reconstruction and measurements of zebrafish larvae and its organs using axial-view microscopy, 2017 IEEE International conference on image processing (ICIP). IEEE International Conference on Image Processing 2017 17 September 2017 - 20 September 2017: IEEE Xplore. 2194-2198.
- Kantae V., Krekels E.H.J., Ordas A.K., Gonzalez O., Wijk R.C. van, Harms A.C., Racz P.I., Graaf P.H. van der, Spaink H.P. & Hankemeier T. (2016), Pharmacokinetic modeling of paracetamol uptake and clearance in zebrafish larvae: expanding the allometric scale in vertebrates with five orders of magnitude, Zebrafish 13(6): 504-510.
- Bellanti F., Wijk R.C. van, Danhof M. & Della Pasqua O.E. (2015), Integration of PKPD relationships into benefit-risk analysis, British Journal of Clinical Pharmacology 80(5): 979-991.
- Chair LMIC Accelerator program
- Chair Global Health Community